Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seagen Inc.
Genmab
Fulgent Pharma LLC.
AstraZeneca
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Gilead Sciences
Arcus Biosciences, Inc.
R-Pharm
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Bayer
Merus B.V.
Pfizer
Boehringer Ingelheim
Institute of Oncology Ljubljana
Memorial Sloan Kettering Cancer Center
Yonsei University
Ohio State University Comprehensive Cancer Center
Poseida Therapeutics, Inc.
Yonsei University
Washington University School of Medicine
Amgen
University of California, Davis
City of Hope Medical Center
University of California, San Diego
UNC Lineberger Comprehensive Cancer Center
Emory University
Roswell Park Cancer Institute
Boundless Bio, Inc.
Seagen Inc.
Boehringer Ingelheim
AbbVie
Aveta Biomics, Inc.
Pfizer
ImmunityBio, Inc.
Canadian Cancer Trials Group
Tianjin Medical University Cancer Institute and Hospital
AbbVie
GlaxoSmithKline
AgonOx, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Novartis
Centre Henri Becquerel